Drugs / NP137
Trials 7 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 14 trials | ||||||
| Phase 1 | NCT06203821 | Sep 2026 → May 2027 expected | malignant pancreatic neoplasm | Aram Hezel | Not yet recruiting | No outcome recorded |
| Phase 1 | NCT05546853 | Mar 2023 → Dec 2024 | pancreatic ductal adenocarcinoma | University Hospital, Grenoble | Completed | No outcome recorded |
| Phase 1 | NCT05546879 | Mar 2023 → Mar 2026 overdue | hepatocellular carcinoma | University Hospital, Grenoble | Active not recruiting | No outcome recorded |
| Phase 1 | NCT02977195 | Jan 2017 → Dec 2021 | endometrial carcinoma, hormone receptor-positive breast cancer | Centre Leon Berard | Completed | No outcome recorded |
| Phase 1/22 trials | ||||||
| Phase 1/2 | NCT06150040 | Sep 2024 → Feb 2025 | acute myeloid leukemia | Centre Leon Berard | Terminated | No outcome recorded |
| Phase 1/2 | NCT04652076 | Dec 2020 → Oct 2025 overdue | cervical carcinoma, endometrial carcinoma | NETRIS Pharma | Active not recruiting | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT05605496 | Jan 2023 → Jan 2027 expected | cancer, metastatic neoplasm | Centre Leon Berard | Active not recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 8 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | NP137 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04652076 ↗ |
| Action | Inhibit | “Pharmacological inhibition of netrin-1 by administration of NP137” PMID 37532929 ↗ Aug 2023 |
| Modality | Monoclonal antibody | “NP137 is a "first-in-class" humanized monoclonal antibody targeting the Netrin-1 ligand” NCT02977195 ↗ |
| Route | Intravenous | “NP137 was administrated every 2 weeks, as single agent by intravenous injection over 90 min” NCT02977195 ↗ |